title: Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response.
abstract: Multiple sclerosis (MS) is postulated to be a T cell-mediated autoimmune disease characterized clinically by a relapsing-remitting (RR) stage followed by a secondary progressive (SP) phase. The progressive phase is felt to be secondary to neuronal degenerative changes triggered by inflammation. The status of the innate immune system and its relationship to the stages of MS is not well understood. Dendritic cells (DCs) are professional APCs that are central cells of the innate immune system and have the unique capacity to induce primary immune responses. We investigated circulating myeloid DCs isolated directly from the blood to determine whether there were abnormalities in myeloid DCs in MS and whether they were related to disease stage. We found that SP-MS subjects had an increased percentage of DCs expressing CD80, a decreased percentage expressing PD-L1, and an increased percentage producing IL-12 and TNF-alpha compared with RR-MS or controls. A higher percentage of DCs from both RR and SP-MS patients expressed CD40 compared with controls. We then investigated the polarization effect of DCs from MS patients on naive T cells taken from cord blood using a MLR assay. Whereas DCs from RR-MS induced higher levels of Th1 (IFN-gamma, TNF-alpha) and Th2 (IL-4, IL-13) cytokines compared with controls, DCs from SP-MS only induced a polarized Th1 response. These results demonstrate abnormalities of DCs in MS and may explain the immunologic basis for the different stages and clinical patterns of MS.
authors.affiliation: Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Havard Medical School, Boston, MA 02115-5817, USA.
authors.forename: Arnon
authors.initials: A
authors.lastname: Karni
authors.forename: Michal
authors.initials: M
authors.lastname: Abraham
authors.forename: Alon
authors.initials: A
authors.lastname: Monsonego
authors.forename: Guifang
authors.initials: G
authors.lastname: Cai
authors.forename: Gordon J
authors.initials: GJ
authors.lastname: Freeman
authors.forename: David
authors.initials: D
authors.lastname: Hafler
authors.forename: Samia J
authors.initials: SJ
authors.lastname: Khoury
authors.forename: Howard L
authors.initials: HL
authors.lastname: Weiner
mesh_terms: D000328:Adult; D039521:CD11c Antigen / Q000096:biosynthesis; D019013:CD40 Antigens / Q000096:biosynthesis / Q000097:blood; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*; D005260:Female; D006801:Humans; D007113:Immunity, Innate; D018836:Inflammation Mediators / Q000097:blood / Q000378:metabolism*; D018664:Interleukin-12 / Q000096:biosynthesis / Q000097:blood; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis; D015854:Up-Regulation / Q000276:immunology
chemical_list: D039521:CD11c Antigen; D019013:CD40 Antigens; D018836:Inflammation Mediators; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12